# Markus Christmann

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 40 papers | 3,063 citations | 257450 24 h-index | 276875 41 g-index |
| 41 all docs | 41 docs citations | 41 times ranked | 4105 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | The Mitochondrial Disruptor Devimistat (CPI-613) Synergizes with Genotoxic Anticancer Drugs in Colorectal Cancer Therapy in a Bim-Dependent Manner. Molecular Cancer Therapeutics, 2022, 21, 100-112. | 4.1 | 9 |
| 2 | Senescence Is the Main Trait Induced by Temozolomide in Glioblastoma Cells. Cancers, 2022, 14, 2233. | 3.7 | 19 |
| 3 | Alterations in Molecular Profiles Affecting Glioblastoma Resistance to Radiochemotherapy: Where Does the Good Go?. Cancers, 2022, 14, 2416. | 3.7 | 13 |
| 4 | Oxaliplatin-Induced Senescence in Colorectal Cancer Cells Depends on p14ARF-Mediated Sustained p53 Activation. Cancers, 2021, 13, 2019. | 3.7 | 14 |
| 5 | Repair of O6-carboxymethylguanine adducts by O6-methylguanine-DNA methyltransferase in human colon epithelial cells. Carcinogenesis, 2021, 42, 1110-1118. | 2.8 | 5 |
| 6 | Localization matters: nuclear-trapped Survivin sensitizes glioblastoma cells to temozolomide by elevating cellular senescence and impairing homologous recombination. Cellular and Molecular Life Sciences, 2021, 78, 5587-5604. | 5.4 | 9 |
| 7 | Natural Merosesquiterpenes Activate the DNA Damage Response via DNA Strand Break Formation and Trigger Apoptotic Cell Death in p53-Wild-Type and Mutant Colorectal Cancer. Cancers, 2021, 13, 3282. | 3.7 | 7 |
| 8 | Targeting c-IAP1, c-IAP2, and Bcl-2 Eliminates Senescent Glioblastoma Cells Following Temozolomide Treatment. Cancers, 2021, 13, 3585. | 3.7 | 19 |
| 9 | Benzo[a]pyrene represses DNA repair through altered E2F1/E2F4 function marking an early event in DNA damage-induced cellular senescence. Nucleic Acids Research, 2020, 48, 12085-12101. | 14.5 | 23 |
| 10 | Lipoic Acid Synergizes with Antineoplastic Drugs in Colorectal Cancer by Targeting p53 for Proteasomal Degradation. Cells, 2019, 8, 794. | 4.1 | 17 |
| 11 | Functional mismatch repair and inactive p53 drive sensitization of colorectal cancer cells to irinotecan via the IAP antagonist BV6. Archives of Toxicology, 2019, 93, 2265-2277. | 4.2 | 13 |
| 12 | DNA repair in personalized brain cancer therapy with temozolomide and nitrosoureas. DNA Repair, 2019, 78, 128-141. | 2.8 | 89 |
| 13 | Temozolomide Induces Senescence and Repression of DNA Repair Pathways in Glioblastoma Cells via Activation of ATRâ€“CHK1, p21, and NF-ÎºB. Cancer Research, 2019, 79, 99-113. | 0.9 | 126 |
| 14 | Epigenetic regulation of DNA repair genes and implications for tumor therapy. Mutation Research - Reviews in Mutation Research, 2019, 780, 15-28. | 5.5 | 59 |
| 15 | Repair gene O<sup>6</sup>â€methylguanineâ€DNA methyltransferase is controlled by SP1 and upâ€regulated by glucocorticoids, but not by temozolomide and radiation. Journal of Neurochemistry, 2018, 144, 139-151. | 3.9 | 41 |
| 16 | Targeting anticancer drug-induced senescence in glioblastoma therapy. Oncotarget, 2018, 9, 37466-37467. | 1.8 | 4 |
| 17 | Inherent and toxicant-provoked reduction in DNA repair capacity: A key mechanism for personalized risk assessment, cancer prevention and intervention, and response to therapy. International Journal of Hygiene and Environmental Health, 2018, 221, 993-1006. | 4.3 | 13 |
| 18 | Sensitization of colorectal cancer cells to irinotecan by the Survivin inhibitor LLP3 depends on XAF1 proficiency in the context of mutated p53. Archives of Toxicology, 2018, 92, 2645-2648. | 4.2 | 13 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Epigenetic silencing of XAF1 in high-grade gliomas is associated with IDH1 status and improved clinical outcome. Oncotarget, 2017, 8, 15071-15084. | 1.8 | 13 |
| 20 | Integrin Î±VÎ²3 silencing sensitizes malignant glioma cells to temozolomide by suppression of homologous recombination repair. Oncotarget, 2017, 8, 27754-27771. | 1.8 | 28 |
| 21 | MGMT promoter methylation determined by HRM in comparison to MSP and pyrosequencing for predicting high-grade glioma response. Clinical Epigenetics, 2016, 8, 49. | 4.1 | 59 |
| 22 | Adaptive upregulation of DNA repair genes following benzo(a)pyrene diol epoxide protects against cell death at the expense of mutations. Nucleic Acids Research, 2016, 44, 10727-10743. | 14.5 | 37 |
| 23 | Apoptosis induced by temozolomide and nimustine in glioblastoma cells is supported by JNK/c-Jun-mediated induction of the BH3-only protein BIM. Oncotarget, 2015, 6, 33755-33768. | 1.8 | 42 |
| 24 | Translesion Polymerase Î· Is Upregulated by Cancer Therapeutics and Confers Anticancer Drug Resistance. Cancer Research, 2014, 74, 5585-5596. | 0.9 | 48 |
| 25 | Human three prime exonuclease TREX1 is induced by genotoxic stress and involved in protection of glioma and melanoma cells to anticancer drugs. Biochimica Et Biophysica Acta - Molecular Cell Research, 2013, 1833, 1832-1843. | 4.1 | 23 |
| 26 | Transcriptional regulation of human DNA repair genes following genotoxic stress: trigger mechanisms, inducible responses and genotoxic adaptation. Nucleic Acids Research, 2013, 41, 8403-8420. | 14.5 | 201 |
| 27 | Survival and Death Strategies in Glioma Cells: Autophagy, Senescence and Apoptosis Triggered by a Single Type of Temozolomide-Induced DNA Damage. PLoS ONE, 2013, 8, e55665. | 2.5 | 218 |
| 28 | O6-methylguanine-DNA methyltransferase (MGMT): impact on cancer risk in response to tobacco smoke. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2012, 736, 64-74. | 1.0 | 40 |
| 29 | O6-Methylguanine-DNA methyltransferase (MGMT) in normal tissues and tumors: Enzyme activity, promoter methylation and immunohistochemistry. Biochimica Et Biophysica Acta: Reviews on Cancer, 2011, 1816, 179-190. | 7.4 | 142 |
| 30 | Delayed c-Fos activation in human cells triggers XPF induction and an adaptive response to UVC-induced DNA damage and cytotoxicity. Cellular and Molecular Life Sciences, 2011, 68, 1785-1798. | 5.4 | 29 |
| 31 | Targeting O 6-methylguanine-DNA methyltransferase with specific inhibitors as a strategy in cancer therapy. Cellular and Molecular Life Sciences, 2010, 67, 3663-3681. | 5.4 | 124 |
| 32 | MGMT activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant gliomas: a comparative study on astrocytoma and glioblastoma. International Journal of Cancer, 2010, 127, 2106-2118. | 5.1 | 97 |
| 33 | Three prime exonuclease I (TREX1) is Fos/AP-1 regulated by genotoxic stress and protects against ultraviolet light and benzo(a)pyrene-induced DNA damage. Nucleic Acids Research, 2010, 38, 6418-6432. | 14.5 | 52 |
| 34 | Differential Sensitivity of Malignant Glioma Cells to Methylating and Chloroethylating Anticancer Drugs: p53 Determines the Switch by Regulating xpc, ddb2, and DNA Double-Strand Breaks. Cancer Research, 2007, 67, 11886-11895. | 0.9 | 96 |
| 35 | MGMT: Key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair, 2007, 6, 1079-1099. | 2.8 | 549 |
| 36 | Inhibition of O6-Methylguanine-DNA Methyltransferase by Glucose-Conjugated Inhibitors: Comparison with Nonconjugated Inhibitors and Effect on Fotemustine and Temozolomide-Induced Cell Death. Journal of Pharmacology and Experimental Therapeutics, 2004, 311, 585-593. | 2.5 | 54 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Mechanisms of human DNA repair: an update. Toxicology, 2003, 193, 3-34. | 4.2 | 486 |
| 38 | Phosphorylation of mismatch repair proteins MSH2 and MSH6 affecting MutSalpha mismatch-binding activity. Nucleic Acids Research, 2002, 30, 1959-1966. | 14.5 | 60 |
| 39 | Acquired resistance of melanoma cells to the antineoplastic agent fotemustine is caused by reactivation of the DNA repair gene mgmt. International Journal of Cancer, 2001, 92, 123-129. | 5.1 | 82 |
| 40 | Nuclear Translocation of Mismatch Repair Proteins MSH2 and MSH6 as a Response of Cells to Alkylating Agents. Journal of Biological Chemistry, 2000, 275, 36256-36262. | 3.4 | 85 |